The Cabral Concept 3667: 600mg of This Supplement May Prevent Cancer (TT)
8 snips
Feb 19, 2026 Breaks down clinical trials showing 600 mg daily of berberine reduced precancerous colorectal polyps and lowered long-term recurrence. Explains how the compound influences blood sugar, AMPK, autophagy and mTOR pathways. Covers anti-inflammatory and microbiome effects from poor absorption. Describes how berberine can trigger apoptosis and gives practical dosing used in studies.
AI Snips
Chapters
Books
Transcript
Episode notes
Berberine Targets Root Causes Of Cancer
- Berberine works on multiple root causes of cancer risk including blood sugar, AMPK activation, and inflammation modulation.
- These combined mechanisms explain why it may reduce colorectal cancer recurrence in humans.
Reviewing Seven Human Trials
- Dr. Stephen Cabral reviewed seven human clinical trials showing berberine lowered colorectal polyp recurrence and cancer progression.
- He emphasizes these were randomized, double-blind trials—the gold standard—showing real human benefit.
Inflammation And Cellular Cleanup Benefits
- Berberine reduces pro-inflammatory signaling like NF-kappa and prostaglandin E2 that fuel cancer growth.
- It also promotes AMPK/autophagy and apoptosis to help remove damaged or malignant cells.
